Drug intelligence / Profile preview

DWC202307

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC202307 is a small molecule drug developed by Daewoong Pharmaceutical Co., Ltd. It is currently in Phase 1 clinical trials, specifically being evaluated for safety and pharmacokinetics in healthy adult volunteers when administered concomitantly with DWJ1543. The primary endpoints of the ongoing study include maximum plasma concentration at steady-state (Cmax,ss) and area under the curve from dosing to last measurable concentration (AUClast) of DWJ1543[1][2][3]. The mechanism of action and specific therapeutic indication have not been publicly disclosed.

Beyond the preview

Go deeper on DWC202307.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202307.

Explore the full profile